Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11β-Methoxy-16α-18F-Fluoroestradiol Using Serial Whole-Body PET/CT

  title={Assessment of Human Biodistribution and Dosimetry of 4-Fluoro-11$\beta$-Methoxy-16$\alpha$-18F-Fluoroestradiol Using Serial Whole-Body PET/CT},
  author={Jean-Mathieu Beauregard and Etienne Croteau and Naseem Ahmed and Johan E van Lier and François B{\'e}nard},
  journal={Journal of Nuclear Medicine},
  pages={100 - 107}
4-Fluoro-11β-methoxy-16α-18F-fluoroestradiol (4FMFES) is a newly developed radiolabeled estradiol analog for PET imaging of estrogen receptors (ERs) that shows improved target-to-background ratios, compared with 16α-18F-fluoroestradiol (FES), in small-animal models. The aim of this study was to assess the biodistribution, dosimetry, and safety of 4FMFES in healthy women. Methods: Ten healthy subjects (6 pre- and 4 postmenopausal women) who had fasted were injected with 66–201 MBq of 4FMFES at a… 

Figures and Tables from this paper

Assessment of the Novel Estrogen Receptor PET Tracer 4-Fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4FMFES) by PET Imaging in a Breast Cancer Murine Model
In a tumor-bearing mouse model, 4FMFES achieves better specific tumor uptake and better contrast than FES, making it a promising candidate for ER imaging.
Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2
The results indicate that [18F]DASA-23 can be used safely in humans to evaluate pyruvate kinase M2 levels and evaluate intracranial malignancies.
Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers
The safety, biodistribution, and internal radiation dosimetry of 18F-rhPSMA-7.3 are considered favorable for PET imaging.
18F-4FMFES and 18F-FDG PET/CT in Estrogen Receptor–Positive Endometrial Carcinomas: Preliminary Report
It is possible to improve 18F-4FMFES abdominal background using hyoscine N-butylbromide, and both 18F/18F-FDG and 4-fluoro-11β-methoxy-16α-18F -fluoroestradiol PET are suitable for detection of ER-positive endometrial cancers, although 18f-4 FMFES yielded a better tumor contrast than did 18F -FDG.
Preclinical Safety Evaluation and Human Dosimetry of [18F]MK-6240, a Novel PET Tracer for Imaging Neurofibrillary Tangles
  • M. Koole, T. Lohith, A. Struyk
  • Medicine, Biology
    Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
  • 2019
Microdoses of [18F]MK-6240 are safe for clinical positron emission tomography imaging studies, and the no-observed-adverse-effect level in rats was ≥ 333 μg/kg/day, which provides a margin 1000-fold over an anticipated maximum clinical dose of 0.333  μG/kg.
18F-ML-10, a PET Tracer for Apoptosis: First Human Study
The first-in-humans study with 18F-labeled 2-(5-fluoropentyl)-2-methyl malonic acid (18F-ML-10), a small-molecule PET tracer for apoptosis, demonstrated a favorable dosimetry, biodistribution, stability, and safety profiles and binding to apoptotic sites was demonstrated.
A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts
A dual-tracer PET imaging approach consisting of a fast- Clearing small molecule and a slow-clearing antibody that can provide high contrast images of tumors expressing ER or HER2 and determines the feasibility of specifically identifying these two important phenotypes in an acceptable time window.
Suggested pathway to assess radiation safety of 18F-labeled PET tracers for first-in-human studies
This commentary will suggest a more accurate alternative that maintains a wide safety margin when predicting the human dose for a given tracer, a simple mean human value from all published studies is a better predictor of the effective dose than the value derived from monkeys for that specific tracer.


Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
The finding of a subset of patients who have tumors that are ER+ and FES- suggests that the functional assessment of hormone sensitivity by PET imaging can identify patients with ER+ disease whose tumors are likely to be hormone refractory.
Biodistribution and dosimetry of iodine-123-labelled Z-MIVE: an oestrogen receptor radioligand for breast cancer imaging
The images showed rapid hepatobiliary excretion which resulted in good imaging conditions for the thoracic region, and the amount of Z-[123I]MIVE required for adequate breast cancer ER imaging results in an acceptable effective dose equivalent to the patient.
Biodistribution and dosimetry of (iodine-123)-iodomethyl-N,N-diethyltamoxifen, an (anti)oestrogen receptor radioligand
The amount of 123-ITX required for adequate imaging of tumoral uptake results in an acceptable effective dose to the patient, and the breast to non-specific uptake ratio increased over time.
Biodistribution and Radiation Dosimetry of the Synthetic Nonmetabolized Amino Acid Analogue Anti-18F-FACBC in Humans
The PET whole-body dosimetry estimates indicate that an approximately 370-MBq injection of anti-18F-FACBC yields good imaging and acceptable dosimetric, and the nonmetabolized nature of this tracer is favorable for extraction of relevant physiologic parameters from kinetic models.
Positron Tomographic Assessment of 16α-[18F] Fluoro-17β-Estradiol Uptake in Metastatic Breast Carcinoma
Results indicate that PET with FES has high sensitivity and specificity for detecting metastatic breast carcinoma and provide additional confirmatory evidence that the tumor uptake of this ligand is a receptormediated process.
[18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice
All of the radiolabelled estradiol derivatives achieved significant target tissue uptake in vivo, both in ER+ tumours and the uterus.
[18F]fluoroestradiol radiation dosimetry in human PET studies.
The organ doses received by FES are comparable to those associated with other commonly performed nuclear medicine tests, and the potential radiation risks associated with this study are well within accepted limits.
18F-labeled difluoroestradiols: preparation and preclinical evaluation as estrogen receptor-binding radiopharmaceuticals
Whole-Body Biodistribution and Radiation Dosimetry of the Human Cannabinoid Type-1 Receptor Ligand 18F-MK-9470 in Healthy Subjects
The estimated radiation burden of 18F-MK-9470 for PET CB1 receptor imaging shows relatively low variability between subjects and has an acceptable ED, which allows multiple serial cerebral scans of good image quality, while remaining within the risk category class II-b defined by the World Health Organization and the International Commission for Radiation Protection.